Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

ITA vs IHI: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

IHI Wins Head-to-Head Institutional Verdict (0–0 across 6 Pillars · 2–1 Matrix Metrics)

IHI Overall Winner 6-Pillar Tally: ITA 0 – 0 IHI (6 Tie) Matrix Metrics: ITA 1 – 2 IHI

As of Nov 16, 2026, iShares U.S. Medical Devices ETF (IHI) is the stronger overall head-to-head candidate over iShares U.S. Aerospace & Defense ETF (ITA) in the Tradestie Institutional Equity Comparison Engine, winning 2–1 core matrix metrics and 0–0 across our 6-pillar institutional scorecard (led by composite factor balance). ITA carries a Unified Composite Score of 51.6/100 (HOLD) at $69.72 (N/M Forward P/E, N/A operating margin), whereas IHI carries 32.0/100 (SELL) at $57.66 (N/M Forward P/E, N/A operating margin).

  • Composite vs. Pillar Nuance: While ITA currently prints a higher short-term Unified Composite Score (51.6/100 HOLD vs. IHI 32.0/100 SELL), IHI captures the overall institutional head-to-head verdict (2–1 matrix metrics and 0–0 across the 6 pillars) due to superior fundamental profitability (N/A vs. N/A operating margin) and revenue trajectory (N/A vs. N/A YoY).
  • Technical & Structure Timing Caution: ITA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 12.3); meanwhile IHI trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 58.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ITA vs IHI
ITA Cboe BZX
iShares U.S. Aerospace & Defense ETF
Institutional Equity
$69.72
-2.51% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 2.92β · 238% Vol
Unified Composite Score
51.6 / 100 HOLD
Tech 60.0 Fund 55.0 Flow 50.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -15.4%), weak momentum, RSI 12
RSI-14: 12.3 · SMA20: $153.74 · SMA50: $188.19
IHI NYSE Arca Head-to-Head Winner
iShares U.S. Medical Devices ETF
Institutional Equity
$57.66
-0.63% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.41β · 34% Vol
Unified Composite Score
32.0 / 100 SELL
Tech 50.0 Fund 30.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (0.9% over 20 days), RSI 58
RSI-14: 58.2 · SMA20: $56.48 · SMA50: $53.69

6-Pillar Scorecard Institutional Category Breakdown (ITA 0 – 0 IHI)

Columns: Metric · ITA · IHI
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale Tie
Revenue Growth (YoY) N/A N/A
Earnings Growth (YoY) N/A N/A
TTM Revenue (USD) N/A N/A
Market Cap N/A N/A
3. Profitability & Quality Tie
Gross Margin N/A N/A
Operating Margin N/A N/A
Net Profit Margin N/A N/A
Return on Equity (ROE) N/A N/A
4. Balance Sheet & Cash Flow Tie
Cash Generation (TTM) N/A N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage N/A ROE N/A ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 20.0% (6th %ile) 17.6% (3rd %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markup
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Institutional Equity Operator Institutional Equity Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ITA (1) vs IHI (2)
Institutional Metric ITA IHI Criterion Row Edge
Market Capitalization
Scale
N/A N/A Larger Scale Tie
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
N/A N/A Higher Growth Tie
Operating Margin (TTM)
Profitability
N/A N/A Higher Margin Tie
Net Profit Margin
Profitability
N/A N/A Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
N/A N/A Higher ROE Tie
52-Week Range Position
Momentum
1% ($67–$257) 59% ($47–$65) Stronger Trend IHI
Beta / 30D Volatility
Risk Regime
2.92β · 238% Vol 0.41β · 34% Vol Lower Realized Risk IHI
Unified Institutional Score
Composite Signal
51.6 / 100 (HOLD) 32.0 / 100 (SELL) Higher Composite ITA
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) N/A (N/A ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon IHI +73.94 pp
ITA: -66.65% · IHI: +7.29%
3M Horizon IHI +76.35 pp
ITA: -72.35% · IHI: +4.0%
6M Horizon IHI +84.16 pp
ITA: -68.34% · IHI: +15.82%
1Y Horizon IHI +57.57 pp
ITA: -66.0% · IHI: -8.43%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ITA vs IHI. Trailing 12-month operating profitability (ITA N/A vs IHI N/A) and valuation multiples (ITA N/M vs IHI N/M Forward P/E) are benchmarked directly in Pillar 4 below.

ITA ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
IHI ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ITA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 20.0%
IV Percentile 6th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ITA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
IHI UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 17.6%
IV Percentile 3rd %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact IHI Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ITA Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
IHI Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ITA vs IHI Key Questions & Quantitative Answers

As of Nov 16, 2026, iShares U.S. Medical Devices ETF (IHI) is the stronger overall head-to-head candidate over iShares U.S. Aerospace & Defense ETF (ITA) in the Tradestie Institutional Equity Comparison Engine, winning 2–1 core matrix metrics and 0–0 across our 6-pillar institutional scorecard (led by composite factor balance). ITA carries a Unified Composite Score of 51.6/100 (HOLD) at $69.72 (N/M Forward P/E, N/A operating margin), whereas IHI carries 32.0/100 (SELL) at $57.66 (N/M Forward P/E, N/A operating margin). Composite vs. Pillar Nuance: While ITA currently prints a higher short-term Unified Composite Score (51.6/100 HOLD vs. IHI 32.0/100 SELL), IHI captures the overall institutional head-to-head verdict (2–1 matrix metrics and 0–0 across the 6 pillars) due to superior fundamental profitability (N/A vs. N/A operating margin) and revenue trajectory (N/A vs. N/A YoY). Technical & Structure Timing Caution: ITA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 12.3); meanwhile IHI trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 58.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ITA and IHI split Growth & Scale metrics: ITA posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with IHI at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, ITA generates N/A in USD-normalized revenue versus N/A for IHI. In operating R&D and SG&A reinvestment, ITA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for IHI.

ITA and IHI trade at balanced relative valuation multiples. ITA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas IHI trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ITA (N/A ROE) versus IHI (N/A ROE) capital efficiency.

In options market volatility and institutional positioning, ITA carries 20.0% implied volatility (6th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.92β · 238% Vol realized risk). By comparison, IHI carries 17.6% implied volatility (3rd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.41β · 34% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.